HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 20.8% | 164.8% | |
| Return on assets | – | – | -32.1% | |
| Current ratio | – | 3.69 | 3.69 | |
| Interest coverage | – | -29.3× | -9.6× | |
| Diluted shares | – | 6M | 158M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Humacyte generated $428.79M from operations and spent $6.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$428.79M
Used
$6.00M
Capital expenditure$6.00M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2003.6%
×Asset turnover0.02×
×Equity multiplier-5.13×
=Return on equity, FY2025164.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2003.6% | 0.02× | -5.13× | 164.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$40.83M
- Cash generatingOperating cash flow above zero-$105.04M
- Return on assets improvedROA up on the prior year-116.0% → -29.6%
- Earnings backed by cashOperating cash flow above net income-$105.04M vs -$40.83M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.40 → 3.69
- No dilutionShare count did not rise118M → 158M
- Gross margin improvedGross margin up on the prior year– → -376.05%
- More efficientAsset turnover rose0.00 → 0.01